Visceral and Subcutaneous Adipose Tissue Assessed by Magnetic Resonance Imaging in Relation to Circulating Androgens, Sex Hormone-Binding Globulin, and Luteinizing Hormone in Young Men

Nielsen, Troels Halfeld; Hagen, Claus; Wraae, Kristian; Brixen, Kim; Petersen, Per Hyltoft; Haug, Egil; Larsen, Rasmus; Andersen, Marianne

doi:10.1210/jc.2006-1847

Cited by 138 publications

(130 citation statements)

References 54 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Testosterone therapy significantly increased LBM in men with bioavailable testosterone<7.3 nmol/l (Nielsen et al 2007). The increase in LBM was not associated with the testosterone level at inclusion.…”

Section: Discussionmentioning

confidence: 91%

“…We chose bioavailable testosterone as SHBG is known to increase with age (Wu et al 2008).We aimed at obtaining bioavailable testosterone within the normal range of bioavailable testosterone in young men (Nielsen et al 2007), hence, the serum total testoster-one levels post treatment would be relatively high. The long-term effects and safety of treatment with testosterone in men with low normal bioavailable testosterone are not known, and further long-term studies are warranted to address this concern.…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, no studies have investigated the effect of testosterone therapy on aging males, assessing insulin sensitivity using the gold standard method, i.e., the euglycemic hyperinsulinemic clamp and substrate oxidation using indirect calorimetry, in a population with low normal bioavailable testosterone levels using a predefined cutoff level for bioavailable testosterone (Nielsen et al 2007). …”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, no studies have investigated the effect of testosterone therapy on insulin sensitivity in aging males with low normal bioavailable testosterone levels defined by a cutoff level for bioavailable testosterone (Nielsen et al 2007) using the gold standard method, the euglycemic hyperinsulinemic clamp. The cutoff level of bioavailable testosterone (7.3 nmol/l) was defined from observations in a thoroughly characterized population of men aged 20-30 years (Nielsen et al 2007).…”

Section: Introductionmentioning

confidence: 99%

“…The cutoff level of bioavailable testosterone (7.3 nmol/l) was defined from observations in a thoroughly characterized population of men aged 20-30 years (Nielsen et al 2007). …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Testosterone therapy increased muscle mass and lipid oxidation in aging men

Frederiksen

Højlund

Hougaard

et al. 2011

AGE

Self Cite

115

View full text Add to dashboard Cite

The indication for testosterone therapy in aging hypogonadal men without hypothalamic, pituitary, or testicular disease remains to be elucidated. The aim of this study was to investigate the effect of testosterone therapy on insulin sensitivity, substrate metabolism, body composition, and lipids in aging men with low normal bioavailable testosterone levels using a predefined cutoff level for bioavailable testosterone. A randomized, double-blinded, placebocontrolled study of testosterone treatment (gel) was done on 38 men, aged 60-78 years, with bioavailable testosterone <7.3 nmol/l and a waist circumference >94 cm. Insulin-stimulated glucose disposal (Rd) and substrate oxidation were assessed by euglycemic hyperinsulinemic clamps combined with indirect calorimetry. Lean body mass (LBM) and total fat mass (TFM) were measured by dual x-ray absorptiometry, and serum total testosterone was measured by tandem mass spectrometry. Bioavailable testosterone was calculated. Coefficients (b) represent the placebo-controlled mean effect of intervention. LBM (b=1.9 kg, p=0.003) increased while HDL-cholesterol (b=−0.12 mmol/l, p=0.043) and TFM decreased (b=−1.2 kg, p=0.038) in the testosterone group compared to placebo. Basal lipid oxidation (b=5.65 mg/min/m 2 , p=0.045) increased and basal glucose oxidation (b=−9.71 mg/min/m 2 , p = 0.046) decreased in response to testosterone therapy even when corrected for changes in LBM. No significant changes in insulin-stimulated Rd was observed (b=−0.01mg/min/m 2 , p=0.92). Testosterone therapy increased muscle mass and lipid oxidation in aging men with low normal bioavailable testosterone levels; however, our data did not support an effect of testosterone on whole-body insulin sensitivity using the euglycemic hyperinsulinemic clamp technique.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…The cutoff level of bioavailable testosterone (7.3 nmol/l) was defined from observations in a thoroughly characterized population of men aged 20-30 years (Nielsen et al 2007). …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations